• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.

作者信息

Calverley David C, Leader Avi, Cheong May Anne, Sanfilippo Kristen M, Mason Ginny, Lyman Gary H, Kuderer Nicole M

机构信息

Section of Hematology/Oncology, Division of Hospital and Specialty Medicine, Portland VA Medical Center, Portland, OR.

Division of Medical Oncology, University of British Columbia Faculty of Medicine, Vancouver, BC, Canada.

出版信息

J Clin Oncol. 2025 Jun 25:JCO2500489. doi: 10.1200/JCO-25-00489.

DOI:10.1200/JCO-25-00489
PMID:40561372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12233209/
Abstract
摘要

相似文献

1
Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.静脉和动脉血栓形成事件的癌症临床试验报告不一致且不准确：紧急呼吁采取行动。
J Clin Oncol. 2025 Jun 25:JCO2500489. doi: 10.1200/JCO-25-00489.
2
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.用于真性红细胞增多症和原发性血小板增多症的抗血小板药物。
Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD006503. doi: 10.1002/14651858.CD006503.pub3.
3
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.用于真性红细胞增多症和原发性血小板增多症的抗血小板药物。
Cochrane Database Syst Rev. 2008 Apr 16(2):CD006503. doi: 10.1002/14651858.CD006503.pub2.
4
D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. A systematic review.D-二聚体作为外周动脉疾病患者心血管和动脉血栓事件的标志物：系统评价。
Thromb Haemost. 2013 Aug;110(2):233-43. doi: 10.1160/TH13-01-0032. Epub 2013 Jun 20.
5
Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis.直接口服抗凝剂与维生素K拮抗剂治疗抗磷脂综合征的系统评价和荟萃分析
Semin Arthritis Rheum. 2025 Aug;73:152741. doi: 10.1016/j.semarthrit.2025.152741. Epub 2025 May 1.
6
Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19.COVID-19 孕妇门诊治疗的血栓和心血管事件的绝对风险低。
Thromb Res. 2024 May;237:209-215. doi: 10.1016/j.thromres.2024.02.021. Epub 2024 Apr 6.
7
Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis.晚期乳腺癌女性使用 CDK4/6 抑制剂治疗的静脉和动脉血栓栓塞事件风险：系统评价和荟萃分析。
Thromb Res. 2021 Dec;208:190-197. doi: 10.1016/j.thromres.2021.11.009. Epub 2021 Nov 17.
8
Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.预防带隧道式中心静脉导管的儿科癌症患者发生静脉血栓栓塞事件的全身治疗。
Cochrane Database Syst Rev. 2013 Sep 11(9):CD009160. doi: 10.1002/14651858.CD009160.pub2.
9
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies.抗血小板和抗凝药物用于抗磷脂抗体个体血栓形成的一级预防。
Cochrane Database Syst Rev. 2018 Jul 13;7(7):CD012534. doi: 10.1002/14651858.CD012534.pub2.
10
Pro-inflammatory markers as predictors of arterial thrombosis in aged patients with peripheral arterial disease post revascularization.促炎标志物作为老年外周动脉疾病患者血管重建术后动脉血栓形成的预测指标。
Front Med (Lausanne). 2025 Jul 24;12:1615816. doi: 10.3389/fmed.2025.1615816. eCollection 2025.

本文引用的文献

1
Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.美国食品和药物管理局批准的抗癌药物的临床研究报告和个体参与者数据透明度：呼吁系统的数据可用性。
J Clin Oncol. 2024 Nov 10;42(32):3773-3777. doi: 10.1200/JCO.24.00539. Epub 2024 Jun 25.
2
VTE with Amivantamab plus Chemotherapy in NSCLC.阿美替尼单抗联合化疗治疗非小细胞肺癌的静脉血栓栓塞症
N Engl J Med. 2024 Feb 8;390(6):578-579. doi: 10.1056/NEJMc2314937.
3
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors.慢性髓性白血病患者在酪氨酸激酶抑制剂治疗期间的动脉闭塞性事件。
Blood. 2024 Mar 7;143(10):858-865. doi: 10.1182/blood.2023022403.
4
Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study.癌症患者中免疫检查点抑制剂治疗与动脉血栓栓塞事件的关联：一项回顾性队列研究。
Cancer Med. 2023 Sep;12(18):18531-18541. doi: 10.1002/cam4.6455. Epub 2023 Aug 16.
5
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.真实世界中使用波那替尼治疗慢性期慢性髓性白血病的经验：反应深度对生存的影响以及先前使用尼洛替尼对动脉闭塞事件的影响。
Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x.
6
Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis.癌症相关孤立性远端深静脉血栓形成患者的临床表现及预后
J Clin Oncol. 2024 Feb 10;42(5):529-537. doi: 10.1200/JCO.23.00429. Epub 2023 Jul 20.
7
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer.肿瘤基因组特征与实体癌患者的动脉血栓栓塞风险相关。
JACC CardioOncol. 2023 Apr 18;5(2):246-255. doi: 10.1016/j.jaccao.2023.01.009. eCollection 2023 Apr.
8
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials.CONSORT危害声明2022：解释与阐述——随机对照试验中危害报告的更新指南
BMJ. 2023 Apr 24;381:e073725. doi: 10.1136/bmj-2022-073725.
9
Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry.下肢浅静脉或深静脉血栓形成的癌症患者的三个月预后：RIETE注册研究结果
Cancers (Basel). 2023 Mar 29;15(7):2034. doi: 10.3390/cancers15072034.
10
Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.在两个独特的美国医疗保健系统中，癌症相关血栓形成的临床风险评估模型的推导和验证。
J Clin Oncol. 2023 Jun 1;41(16):2926-2938. doi: 10.1200/JCO.22.01542. Epub 2023 Jan 10.